Beta Disclaimer
User Name:
Password:
Create New Account
Forgot Password?
Open Login in a new window
USEF Login
Home
About USEF
2010 Annual Meeting
Who We Are
Staff Directory
Customer Care Center
Contact Us
Committee List
ShopUSEF.com
Sponsorship
Charitable Giving
For the Record
Employment
Membership
Sign In
Join or Renew
Affiliate with USEF
Customer Care Center
MemberPerks
Forms & Guidelines
Subscriptions
Youth Programs
EQ Verification
Horse Services
Forms & Guidelines
PHR / APH
Results Search
Measurement Search
Recording Search
Horse FAQ's
Breeds
Recognized National
Breed Affiliates
Andalusian/Lusitano
Arabian
Connemara
Friesian
Hackney
Morgan
National Show Horse
Paso Fino
Saddlebred
Shetland
Welsh Pony/Cob
Disciplines
International
Combined Driving
Dressage
Endurance
Eventing
Jumping
Para-Equestrian
Reining
Vaulting
Athlete Services (Competing Abroad)
National
Pleasure Driving
Hunter
Hunter Seat Equitation
Parade Horse
Roadster
Saddle Seat Equitation
Western
Western/Reining Seat Eq
Competitions
Calendar
Athlete Resources
Competition Management
Drugs & Medications
FEI Organizers
Points & Standings
Points & Standings
Awards
Rules & Regulation
Rule Book
Suspension List
Rulings
Drugs & Medications
Officials & Education
Licensed Officials
Education
News & Media
Who We Are
News Releases
Media Guides
Equestrian Magazine
Week In Review News
PHR Newsletter
Advertising
2009 Media Awards
Search
USEF.org
Competitions
Horse Results
Horse Measurements
Horse Recording / ID
Memberships
Amateur Status
Suspended Exhibitors
Farms
FEI Registrations
Forms & Guidelines
Licensed Officials
Horse Roster
Membership Roster
Equine.com Classifieds
Printer Friendly Version
Email This Post
Share this post:
New Research Demonstrates Phenylbutazone Risks
Release:
March 18 2009
Author:
severs
By Natasha Joseph
New research demonstrates that prolonged administration of phenylbutazone (bute) can cause some adverse effects in horses as soon as three days after initial treatment. The effects include protein loss, lowered white blood cell counts, blood flow changes in the right dorsal colon and changes in volatile fatty acid activity. [1]
“Every veterinarian should be aware of this important research,” said Frank Hurtig, DVM, MBA, Director, Merial Veterinary Services. “We applaud Dr. McConnico and her team for their hard work and contribution to our knowledge of this subject.”
The research team’s goal was to focus on the effects in individual horses, noted lead researcher Rebecca S. McConnico, DVM, PhD, Dipl. ACVIM, associate professor, Louisiana State University School of Veterinary Medicine.
“The research will serve its purpose if we take a moment to look at individual horses and assess the possible toxic effects of this drug,” said Dr. McConnico.
During the study, eight horses were either administered bute at 8.8 mg/kg for 21 days, or were part of the control group given corn syrup. The horses were closely monitored using physical examinations, blood samples, arterial blood flow analysis examinations and samples collected from the right dorsal colon as well as other analyses. [1]
Horses receiving bute experienced: [1]
· Abnormally low protein concentrations in the blood stream beginning as early as three days after the initial administration of bute.
· A low number of white blood cells starting three to six days after initial treatment.
· Concentrations of one type of volatile fatty acid lowered significantly in just two weeks.
Dr. McConnico noted that volatile fatty acids are largely thought to be responsible for water absorption in the distal part of the colon in horses. In addition to these results, two horses developed colitis while receiving bute and were removed from the study and hospitalized. [1]
Without the detailed measurement undertaken in this research, the outward signs of these effects would be subtle, Dr. McConnico noted.
“It’s not necessarily what the average horse owner would see; it’s almost what you wouldn’t see,” Dr. McConnico said. “You wouldn’t see the horse at its best physically. These fluctuations could really affect a horse’s ability to perform.”
With the support of the Grayson Jockey Club Research Foundation, the study’s five authors addressed these questions and have made strides to determine the commonplace medication’s potential effects.
“This research brings to light individual animal variability,” Dr. McConnico said. “There are a whole lot of medications where we don’t quite know what they’re doing to the animal’s entire system. Hopefully, we’ll continue down this path of research and sort that out for the horses’ benefit.”
The labor-intensive study encountered a few surprises, including an interruption by Hurricane Katrina in 2005. Despite setbacks, the findings begin to confirm anecdotal evidence gathered over the course of Dr. McConnico’s career. "During my graduate program and working in referral practices, we would tend to see cases that were a little more unusual,” Dr. McConnico said. “In many of those cases, it seemed to many of us that bute has not been tolerated well in a large number of horses. However, some horses could tolerate it. We felt we needed to look at bute use in the long term, which is what this research accomplished.”
Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs approximately 5,400 people and operates in more than 150 countries worldwide. Its 2008 sales were over $2.6 billion. Merial Limited is a joint venture between Merck & Co., Inc., and sanofi-aventis. For more information, please see
News Releases
Press Release Archive
Around the World News
Home
|
About USEF
|
Membership
|
Horse Services
|
Breeds
|
Disciplines
|
Competitions
|
Points & Standings
Rules & Regulation
|
Officials & Education
|
News & Media
|
Search
|
Photo Credits
|
Site Map